Blood Preparation Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Blood Preparation Market Report is Segmented by Product Type (Whole Blood, Blood Components, and Blood Derivatives), Blood Thinning Agents (Anticoagulants, and More), Application (Thrombocytosis, and More), End User (Hospitals & Surgical Centers, and More), Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Blood Preparation Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Blood Preparation Market with other markets in Healthcare Industry

Blood Preparation Market Analysis by Mordor Intelligence

The blood preparation market was valued at USD 56.55 billion in 2025 and is forecast to reach USD 76.50 billion by 2030, registering a 6.23% CAGR during the period. This trajectory is supported by the growing adoption of automated component separation, the spread of pathogen-reduction platforms, and steady growth in surgical volumes that elevate transfusion demand. Parallel expansion in plasma-derived therapeutics, especially immunoglobulins, underscores a move toward precision medicine and chronic-disease management. Consolidation among plasma fractionators is lowering cost per liter and improving supply resilience, while new anticoagulant classes such as factor XI inhibitors are widening clinical use cases. Across regions, robust regulatory frameworks in North America and capacity build-outs in Asia-Pacific create a balanced demand–supply dynamic that sustains long-term growth for the blood preparation market.

Key Report Takeaways

  • By product type, blood derivatives led with 48.45% revenue share in 2024, whereas blood components are projected to advance at an 8.56% CAGR through 2030.
  • By blood-thinning agent, anticoagulants commanded 61.45% of the blood preparation market share in 2024, while platelet aggregation inhibitors are forecast to grow at 8.73% CAGR to 2030.
  • By application, pulmonary embolism accounted for 27.56% of the blood preparation market size in 2024, while renal impairment shows the quickest expansion at 9.24% CAGR between 2025-2030.
  • By end user, hospitals and surgical centers captured 45.89% share of the blood preparation market in 2024; blood and plasma banks exhibit the fastest 9.65% CAGR through 2030.
  • By geography, North America dominated with 38.54% share in 2024, whereas Asia-Pacific registers a 7.56% CAGR, the highest regional pace.

Segment Analysis

By Product Type: Blood Derivatives Lead Despite Component Innovation

Blood derivatives held 48.45% of 2024 revenue, anchored by strong immunoglobulin and coagulation factor demand. The pulmonary embolism segment accounted for 27.56% share of the blood preparation market size in 2024, supporting derivative consumption in acute settings. CSL Behring logged 20% sales growth for immunoglobulins, aided by a 22% drop in plasma collection cost per liter, illustrating scale economics that favor large fractionators. Automated systems such as Reveos drive 8.56% CAGR for blood components, delivering higher platelet and red-cell yields per unit, lowering wastage, and extending storage times from 42 to 63 days through super-cooling preservation. Increasing hospital adoption of component-specific transfusion protocols sustains this expansion for the blood preparation market.

The derivatives pipeline remains buoyant. Grifols projects USD 1 billion cumulative sales for Yimmugo over seven years post-FDA approval. European governments aim to reach 80% self-sufficiency in albumin by 2030, stimulating domestic contract fractionation programs. Parallel advances in whole-blood robotics and artificial substitutes offer long-range alternatives but will take time to displace established derivatives. Consequently, derivatives retain leadership even as component innovation elevates the efficiency and profitability of the blood preparation market.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Blood Thinning Agents: Anticoagulant Dominance Faces Innovation Pressure

Anticoagulants represented 61.45% of 2024 revenue, reflecting entrenched clinical guidelines and physician familiarity. Abelacimab, a factor XI inhibitor, reduced bleeding by 67% versus rivaroxaban in atrial-fibrillation trials, propelling platelet-aggregation inhibitor growth at an 8.73% CAGR. Apixaban remained Australia’s most prescribed oral anticoagulant, costing the health system USD 500 million in 2024. The pulmonary embolism segment captured 27.56% share of the blood preparation market, reinforcing anticoagulant volumes across emergency and chronic settings.

Four-factor prothrombin complex concentrate is displacing frozen plasma during cardiac surgery, lowering major bleeding by nearly 50%. Fibrinolytics hold steady demand but face increasing competition from recombinant hemostatic drugs that shorten infusion times. As factor XI agents enter late-stage development, prescribing patterns may pivot, but established anticoagulants will continue to anchor revenue for the blood preparation market during the forecast horizon.

By Application: Pulmonary Embolism Leadership Challenged by Renal Growth

Pulmonary embolism held 27.56% revenue share in 2024, supported by upgraded imaging and risk-stratification tools that encourage earlier intervention. Within this cohort, factor XI inhibitors are expected to capture share because they minimize bleeding risks in high-thrombotic states. Renal impairment therapies expand at 9.24% CAGR, reflecting the growing chronic-kidney-disease patient base in Asia-Pacific and the need for specialized anticoagulation protocols. Precision dosing algorithms based on glomerular-filtration rates are improving safety and reducing readmissions, enhancing adoption across nephrology clinics.

Thrombocytosis management leverages novel aggregation inhibitors, and cancer-associated thrombosis drives additional uptake of low-molecular-weight heparins. Pediatric anticoagulation remains niche but is poised for growth as safety data become more robust. These shifts illustrate how tailored therapies sustain demand diversification within the blood preparation market.

Blood Preparation Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By End User: Hospital Dominance Shifts Toward Specialized Centers

Hospitals and surgical centers secured 45.89% of 2024 revenue, benefiting from integrated blood-management programs that reduced wastage by 12% at leading U.S. academic centers. Nonetheless blood and plasma banks will grow 9.65% CAGR as apheresis automation enables higher throughput without extra donations, enhancing cost efficiency for regional blood systems. Sanquin’s national roll-out of Reveos added capacity equivalent to 90,000 additional platelet pools annually without additional donors.

Ambulatory surgery centers deploy point-of-care hemoglobin testing that shortens pre-op screening to five minutes, supporting decentralized care. Home-health providers increasingly use capillary collection devices that deliver venous-quality samples, broadening access for chronic-disease monitoring. The changing end-user mix highlights the flexibility and reach of the blood preparation market.

Geography Analysis

North America retained 38.54% of 2024 revenue, underpinned by 350 CSL Plasma donor centers and rapid uptake of the Rika collection system, which cuts donation time by 15 minutes. The region’s elaborate regulatory agenda, with five blood-focused guidance documents slated for 2025, accelerates technology approval and adoption[3]Federal Register, “Renewal of the Blood Products Advisory Committee,” federalregister.gov. Yet climate disruptions dent supply: the American Red Cross saw a 25% inventory drop in July 2024 during extreme heat and storms.

Asia-Pacific registers the highest 7.56% CAGR. Terumo’s USD 15 million Hangzhou plant enhances local production, while Indonesia’s plasma-fractionation project fast-tracks regional self-sufficiency. Japan’s artificial-blood program at Nara Medical University could revolutionize emergency transfusion with two-year shelf life and universal compatibility.

Europe focuses on autonomy under the new SoHO regulation, requiring 2 million extra donors and common quality standards across member states. The United Kingdom is on track for 25% immunoglobulin self-sufficiency by 2025, aided by domestic fractionation contracts gov.uk. Sanquin’s adoption of automated processing in the Netherlands demonstrates how technology reduces dependence on incremental donations. These geographic dynamics collectively reinforce a balanced global outlook for the blood preparation market.

Blood Preparation Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The blood preparation market is moderately concentrated. The combined plasma therapy revenue of CSL, Takeda, and Grifols exceeds USD 30 billion, giving the top tier bargaining power with regulators and payers. CSL raised profit 15% in 2024 by trimming plasma-collection cost per liter by 22% and launching gene therapy HEMGENIX for hemophilia B. Grifols posted EUR 6.592 billion revenue but is evaluating divestitures to streamline debt.

Strategic focus pivots toward vertical integration and technology differentiation. Haemonetics divested its whole-blood segment for USD 67 million to concentrate on higher-margin apheresis and plasma systems. Cerus grew revenue 20% as its INTERCEPT platform became a standard for Canadian Blood Services. Device innovators pursue robotics, while biotech entrants develop lab-grown blood and artificial substitutes that could disrupt incumbent plasma fractions.

White-space opportunities include decentralized testing, emerging-market fractionation, and pathogen-inactivated red-cell products. However the discontinuation of Pfizer’s Beqvez gene therapy after FDA approval underscores market-acceptance challenges for high-price advanced therapies. Overall, firms that marry scale with technological edge are best positioned to gain share in the blood preparation market.

Blood Preparation Industry Leaders

  1. CSL Behring

  2. Takeda Pharmaceutical Co.

  3. Takeda Pharmaceutical Co. Baxter International

  4. Grifols S.A

  5. Octapharma AG

  6. *Disclaimer: Major Players sorted in no particular order
Blood Preparation Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • March 2025: Sanofi secured FDA approval for Qfitlia (fitusiran), reducing annualized bleeding episodes by 71-73% in hemophilia A and B with six injections per year.
  • March 2025: DHL Group acquired CRYOPDP, enhancing cold-chain capacity for blood products and cell therapies across 15 countries.
  • February 2025: Pfizer halted Beqvez commercialization due to limited uptake despite FDA approval, illustrating adoption hurdles for premium gene therapies.
  • February 2025: Terumo Blood and Cell Technologies launched Reveos in the United States with Blood Centers of America, automating four-unit whole-blood separation in one spin.
  • January 2025: Haemonetics Corporation closed the sale of its whole-blood assets to GVS for USD 67.8 million to sharpen focus on apheresis and plasma technologies.

Table of Contents for Blood Preparation Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope Of The Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Global Surgical Procedures Volume
    • 4.2.2 Growing Prevalence of Chronic And Hematologic Disorders
    • 4.2.3 Rising Government Support for Blood Collection Infrastructure
    • 4.2.4 Advancements in Blood Screening and Processing Technologies
    • 4.2.5 Expansion of Plasma-Derived Therapeutics Portfolio
    • 4.2.6 Growing Adoption of Novel Oral Anticoagulants
  • 4.3 Market Restraints
    • 4.3.1 Risk of Transfusion-Transmitted Infections
    • 4.3.2 High Cost of Advanced Blood Preparation Technologies
    • 4.3.3 Supply Chain Constraints for Donor Plasma and Heparin
    • 4.3.4 Inadequate Cold Chain and Storage Facilities in Developing Regions
  • 4.4 Regulatory Landscape
  • 4.5 Porter's Five Forces Analysis
    • 4.5.1 Threat Of New Entrants
    • 4.5.2 Bargaining Power Of Buyers
    • 4.5.3 Bargaining Power Of Suppliers
    • 4.5.4 Threat Of Substitutes
    • 4.5.5 Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Product Type
    • 5.1.1 Whole Blood
    • 5.1.2 Blood Components
    • 5.1.2.1 Red Blood Cells
    • 5.1.2.2 Platelets
    • 5.1.2.3 Plasma
    • 5.1.3 Blood Derivatives
    • 5.1.3.1 Immunoglobulins
    • 5.1.3.2 Coagulation Factors VIII & IX
    • 5.1.3.3 Albumin
  • 5.2 By Blood Thinning Agents
    • 5.2.1 Anticoagulants
    • 5.2.2 Fibrinolytics
    • 5.2.3 Platelet Aggregation Inhibitors
  • 5.3 By Application
    • 5.3.1 Thrombocytosis
    • 5.3.2 Pulmonary Embolism
    • 5.3.3 Renal Impairment
    • 5.3.4 Other Applications
  • 5.4 By End User
    • 5.4.1 Hospitals & Surgical Centers
    • 5.4.2 Blood & Plasma Banks
    • 5.4.3 Other End Users
  • 5.5 Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)
    • 6.3.1 CSL Behring
    • 6.3.2 Takeda Pharmaceutical Co.
    • 6.3.3 Baxter International
    • 6.3.4 Grifols S.A
    • 6.3.5 Octapharma AG
    • 6.3.6 Pfizer Inc
    • 6.3.7 Bayer AG
    • 6.3.8 Sanofi S.A
    • 6.3.9 Bristol-Myers Squibb
    • 6.3.10 Boehringer Ingelheim
    • 6.3.11 Daiichi Sankyo
    • 6.3.12 GlaxoSmithKline PLC
    • 6.3.13 Leo Pharma
    • 6.3.14 Abbott Laboratories
    • 6.3.15 Haemonetics Corporation
    • 6.3.16 Terumo BCT Inc.
    • 6.3.17 Fresenius Kabi
    • 6.3.18 Medtronic PLC (Blood Management)
    • 6.3.19 American Red Cross
    • 6.3.20 Kedrion S.p.A.

7. Market Opportunities & Future Outlook

  • 7.1 White-Space & Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Blood Preparation Market Report Scope

Blood preparation involves a typical blood establishment process from collection to storage and transfer to hospitals for critical cases. Blood becomes an essential factor during life-threatening conditions, supportive therapy for surgery, chemotherapy, and stem cell and organ transplantation. 

 The Blood Preparation Market is Segmented by Product Type (Blood Components, Whole Blood, and Blood Derivatives), Blood Thinning Agents (Fibrinolytic, Anticoagulants, and Platelet Aggregation Inhibitor), Application (Thrombocytosis, Pulmonary Embolism, Renal Impairment, and Other Applications) and Geography (North America (United States, Canada, and Mexico), Europe ) Germany, United Kingdom, France, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, and the Rest of Middle East and Africa), and South America Brazil, Argentina, and Rest of South America)). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers value (in USD million) for the above segments.

By Product Type Whole Blood
Blood Components Red Blood Cells
Platelets
Plasma
Blood Derivatives Immunoglobulins
Coagulation Factors VIII & IX
Albumin
By Blood Thinning Agents Anticoagulants
Fibrinolytics
Platelet Aggregation Inhibitors
By Application Thrombocytosis
Pulmonary Embolism
Renal Impairment
Other Applications
By End User Hospitals & Surgical Centers
Blood & Plasma Banks
Other End Users
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
By Product Type
Whole Blood
Blood Components Red Blood Cells
Platelets
Plasma
Blood Derivatives Immunoglobulins
Coagulation Factors VIII & IX
Albumin
By Blood Thinning Agents
Anticoagulants
Fibrinolytics
Platelet Aggregation Inhibitors
By Application
Thrombocytosis
Pulmonary Embolism
Renal Impairment
Other Applications
By End User
Hospitals & Surgical Centers
Blood & Plasma Banks
Other End Users
Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current value of the blood preparation market?

The blood preparation market size stood at USD 56.55 billion in 2025 and is projected to reach USD 76.50 billion by 2030 at a 6.23% CAGR.

Which segment is growing fastest within the blood preparation market?

Blood components are expanding most rapidly, posting an 8.56% CAGR through 2030 due to wider adoption of automated separation systems.

Who holds the largest share of the blood preparation market by geography?

North America leads with 38.54% market share in 2024, driven by extensive plasma-collection infrastructure and supportive regulation.

How are factor XI inhibitors influencing anticoagulant therapy?

Factor XI inhibitors such as abelacimab reduce major bleeding up to 67% compared with older anticoagulants, fueling 8.73% CAGR for platelet aggregation inhibitors.

What technologies are modernizing blood preparation processes?

Automation platforms like Terumo’s Reveos, pathogen-reduction systems from Cerus, and robotic phlebotomy devices are shortening processing times, improving safety, and lowering costs for blood centers.

Why is Asia-Pacific considered the most attractive growth region?

A 7.56% CAGR is supported by healthcare modernization, new fractionation plants, and localization investments by multinational firms, enhancing supply security and access to plasma-derived therapies.

Page last updated on: June 20, 2025

Blood Preparation Market Report Snapshots